Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Med Chem Lett ; 14(12): 1882-1890, 2023 Dec 14.
Article in English | MEDLINE | ID: mdl-38116431

ABSTRACT

Precise length, shape, and linker attachment points are all integral components to designing efficacious proteolysis targeting chimeras (PROTACs). Due to the synthetic complexity of these heterobifunctional degraders and the difficulty of computational modeling to aid PROTAC design, the exploration of structure-activity relationships remains mostly empirical, which requires a significant investment of time and resources. To facilitate rapid hit finding, we developed capabilities for PROTAC parallel synthesis and purification by harnessing an array of preformed E3-ligand-linker intermediates. In the next iteration of this approach, we developed a rapid, nanomole-scale PROTAC synthesis methodology using amide coupling that enables direct screening of nonpurified reaction mixtures in cell-based degradation assays, as well as logD and EPSA measurements. This approach greatly expands and accelerates PROTAC SAR exploration (5 days instead of several weeks) as well as avoids laborious and solvent-demanding purification of the reaction mixtures, thus making it an economical and more sustainable methodology for PROTAC hit finding.

3.
Assay Drug Dev Technol ; 18(4): 157-179, 2020.
Article in English | MEDLINE | ID: mdl-32407132

ABSTRACT

Evaluation and optimization of physicochemical and metabolic properties of compounds are a crucial component of the drug development process. Continuous access to this information during the design-make-test-analysis cycle enables identification of chemical entities with suitable properties for efficient project progression. In this study, we describe an integrated and automated assay panel (DMPK Wave 1) that informs weekly on lipophilicity, solubility, human plasma protein binding, and metabolic stability in rat hepatocytes and human liver microsomes. All assays are running in 96-well format with ultraperformance liquid chromatography-mass spectrometry (MS)/MS as read-out. A streamlined overall workflow has been developed by optimizing all parts of the process, including shipping of compounds between sites, use of fit-for-purpose equipment and information systems, and technology for compound requesting, data analysis, and reporting. As a result, lead times can be achieved that well match project demands across sites independently of where compounds are synthesized. This robust screening strategy is run on a weekly basis and enables optimization of structure-activity relationships in parallel with DMPK properties to allow efficient and informed decision making.


Subject(s)
Pharmaceutical Preparations/chemistry , Pharmaceutical Preparations/metabolism , Animals , Automation , Chromatography, High Pressure Liquid , Hepatocytes/chemistry , Hepatocytes/metabolism , Humans , Mass Spectrometry , Microsomes, Liver/chemistry , Microsomes, Liver/metabolism , Rats
4.
Chemistry ; 24(12): 2832-2836, 2018 Feb 26.
Article in English | MEDLINE | ID: mdl-29211300

ABSTRACT

Inhibition of the sodium-glucose co-transporters (SGLT1 and SGLT2) is a validated strategy to address the increasing prevalence of type II diabetes mellitus. However, achieving selective inhibition of human SGLT1 or SGLT2 remains challenging. Orally available small molecule drugs based on the d-glucose core of the natural product Gliflozin have proven to be clinically effective in this regard, effectively impeding glucose reabsorption. Herein, we disclose the influence of molecular editing with fluorine at the C2 position of the pyranose ring of Phlorizin analogues Remogliflozin Etabonate and Dapagliflozin (Farxiga® ) to concurrently direct ß-selective glycosylation, as is required for biological efficacy, and enhance aspects of the physicochemical profile. Given the abundance of glycosylated pharmaceuticals in diabetes therapy that contain a ß-configured d-glucose nucleus, it is envisaged that this strategy may prove to be expansive.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Fluorine/chemistry , Hypoglycemic Agents/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors , Administration, Oral , Benzhydryl Compounds/therapeutic use , Blood Glucose/metabolism , Glucosides/therapeutic use , Glycosylation , Humans , Pyrazoles/therapeutic use
5.
J Med Chem ; 49(23): 6660-71, 2006 Nov 16.
Article in English | MEDLINE | ID: mdl-17154497

ABSTRACT

A multivariate analysis of drugs on the Swedish market was the basis for the selection of a small, physicochemically diverse set of 24 drug compounds. Factors such as structural diversity, commercial availability, price, and a suitable analytical technique for quantification were considered in the selection. Lipophilicity, pKa, solubility, and permeability across human Caco-2 cell monolayers were measured for the compiled data set. The results show that, by use of a physicochemically diverse data set, experimental responses over a wide range were obtained. The paper also shows how experimental difficulties due to the diversity of the data set can be overcome. We anticipate that this data set can serve as a benchmark set for validation of new experimental techniques or in silico models. It can also be used as a diverse starting data set for the development of new computational models.


Subject(s)
Drug Design , Pharmaceutical Preparations/chemistry , Caco-2 Cells , Cell Membrane Permeability , Chemistry, Pharmaceutical , Chromatography, Liquid/methods , Humans , Hydrogen-Ion Concentration , Ions , Molecular Structure , Multivariate Analysis , Pharmaceutical Preparations/metabolism , Pharmacokinetics , Solubility , Spectrophotometry, Ultraviolet
SELECTION OF CITATIONS
SEARCH DETAIL
...